Grifols Prf Class B (GRLSbn)

Currency in EUR
7.900
0.000(0.00%)
Delayed Data·
GRLSbn is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.9008.050
52 wk Range
6.1408.230
Key Statistics
Bid/Ask
8.11 / 8.11
Prev. Close
7.9
Open
8.05
Day's Range
7.9-8.05
52 wk Range
6.14-8.23
Volume
56.17K
Average Volume (3m)
99.6K
1-Year Change
4.4283%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GRLSbn Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.280
Upside
+17.47%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

Grifols Prf Class B News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

Analyst Ratings

2 Buy
1 Hold
1 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 9.280
(+17.47% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Barclays
Buy13.00+64.56%12.50Maintain04-11-2026
BofA Securities
Buy10.00+26.58%-Maintain04-09-2026
BofA Securities
Buy13.00+64.56%-Maintain04-09-2026
Deutsche Bank
Hold10.00+26.58%11.00Maintain11-05-2026
Barclays
Buy12.50+58.23%13.50Maintain23-04-2026

Earnings

Latest Release
02-11-2026
EPS / Forecast
0.30 / 0.26
Revenue / Forecast
2.04B / 1.97B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.72
Dividend Yield
2.49%
Industry Median 2.62%
Annualised payout
0.20
Paid unevenly
5-Years Growth
-1.53%
Growth Streak

GRLSbn Income Statement

Compare GRLSbn to Peers and Sector

Metrics to compare
GRLSbn
Peers
Sector
Relationship
P/E Ratio
14.2x26.7x−0.2x
PEG Ratio
-0.140.00
Price/Book
1.2x2.5x2.6x
Price / LTM Sales
0.9x3.0x2.8x
Upside (Analyst Target)
17.5%14.2%65.0%
Fair Value Upside
Unlock3.3%9.5%Unlock

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Employees
25000
Market
Spain

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
159.50M23.44%1.26B
Other Institutional Investors
330.70M48.59%2.61B
Public Companies & Retail Investors
190.38M27.97%1.50B
Total
680.58M100.00%5.38B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Brandes Investment Partners, LP9.56%6,50,36,4645,13,788
Deria S.A.9.52%6,47,87,3665,11,820

FAQ

What Is the Grifols Prf Class B (GRLSbn) Share Price Today?

The Grifols Prf Class B share price today is 7.900.

What is the current Grifols Prf Class B (GRLSbn) share price and day range?

As of 16-11-2026, the Grifols Prf Class B share price is 7.900, with a previous close of 7.900. The share price has ranged from 7.900 to 8.050 today, while the 52-week range spans from 6.140 to 8.230.

What Is the Grifols Prf Class B Market Cap?

As of today, Grifols Prf Class B market cap is 6.960B.

Does Grifols Prf Class B Pay Dividends? What's The Current Dividend Yield?

The Grifols Prf Class B dividend yield is 2.5%%.

What Is the Grifols Prf Class B (GRLSbn) Share Price Target?

The average 12-month share price target for Grifols Prf Class B is 9.280, with a high estimate of 12.1 and a low estimate of 6.3. 2 analysts recommend buying, while 1 suggest selling, with an overall rating of Buy and +17.47% Upside potential.

What Is Grifols Prf Class B's Earnings Per Share (TTM)?

The Grifols Prf Class B EPS (TTM) is 0.72.

When Is the Next Grifols Prf Class B Earnings Date?

Grifols Prf Class B will release its next earnings report on 04-03-2027.

From a Technical Analysis Perspective, Is GRLSbn a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

What Stock Exchange Does Grifols Prf Class B Trade On?

Grifols Prf Class B is listed and trades on the Madrid Stock Exchange.

What Is the Stock Symbol for Grifols Prf Class B?

The stock symbol for Grifols Prf Class B is "GRLSbn."

How Many Times Has Grifols Prf Class B Stock Split?

Grifols Prf Class B has split 3 times.

How Many Employees Does Grifols Prf Class B Have?

Grifols Prf Class B has 25000 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.